Valneva SE (VALN): Price and Financial Metrics


Valneva SE (VALN): $24.41

0.59 (+2.48%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VALN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

VALN POWR Grades


  • VALN scores best on the Value dimension, with a Value rank ahead of 86.59% of US stocks.
  • The strongest trend for VALN is in Quality, which has been heading down over the past 179 days.
  • VALN ranks lowest in Momentum; there it ranks in the 4th percentile.

VALN Stock Summary

  • With a one year PEG ratio of 2.56, Valneva SE is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than just 11.22% of US stocks.
  • VALN's went public 0.9 years ago, making it older than merely 0.09% of listed US stocks we're tracking.
  • As for revenue growth, note that VALN's revenue has grown 187.78% over the past 12 months; that beats the revenue growth of 95.68% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Valneva SE are IMMP, GLPG, HIMX, ERYP, and GMAB.
  • To dig deeper into the stock's financial statements, go to VALN's page on browse-edgar?action=getcompany&CIK=0001836564.

VALN Stock Price Chart Interactive Chart >

Price chart for VALN

VALN Price/Volume Stats

Current price $24.41 52-week high $67.84
Prev. close $23.82 52-week low $19.45
Day low $24.00 Volume 7,300
Day high $24.71 Avg. volume 38,330
50-day MA $29.84 Dividend yield N/A
200-day MA $37.73 Market Cap 1.31B

Valneva SE (VALN) Company Bio


Valneva SE, a specialty vaccine company, focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; and DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium. The company also develops VLA15, a vaccine candidate that is in Phase II clinical trial against Borrelia; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; and VLA2001, a vaccine candidate that has completed Phase I/II clinical trial against SARS-CoV-2. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. The company has collaborations with Pfizer to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. Valneva SE was incorporated in 1999 and is headquartered in Saint-Herblain, France.


VALN Latest News Stream


Event/Time News Detail
Loading, please wait...

VALN Latest Social Stream


Loading social stream, please wait...

View Full VALN Social Stream

Latest VALN News From Around the Web

Below are the latest news stories about Valneva SE that investors may wish to consider to help them evaluate VALN as an investment opportunity.

Valneva Secures £20M From Scottish Enterprise For Vaccine Development

Valneva SE (NASDAQ: VALN) has been awarded research and development funding of up to £20 million by Scottish Enterprise. The investment from Scotland's national economic development agency will comprise two grants and benefit the company's manufacturing site in Livingston. The company expects to receive grants over the next three years, commencing March 2022. The first grant of up to £12.5 million will support research and development related to the manufacture of VLA2001, Valneva's inactivated,

Yahoo | February 22, 2022

Valneva Awarded Up to £20 Million by Scottish Enterprise to Advance Vaccine Development

Saint Herblain (France), February 21, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its subsidiary Valneva Scotland has been awarded research and development funding of up to £20 million by Scottish Enterprise. The investment from Scotland’s national economic development agency follows advanced discussions reported on December 23, 2021, and will be comprised of two grants, which build on the agency’s longstanding engagement with Valneva

Yahoo | February 21, 2022

VALNEVA SE Declaration of shares and voting rights - January 2022

VALNEVA Declaration of shares and voting rights January 31, 2022__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: February 4, 2022 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the changeDate on which this change

Yahoo | February 4, 2022

Valneva - Pfizer Choose Three-Dose Schedule For Lyme Vaccine Candidate Moving Forward

Valneva SE (NASDAQ: VALN) and Pfizer Inc (NYSE: PFE) have reported further Phase 2 data for their Lyme disease vaccine candidate, VLA15. The Phase 2 trial, VLA15-221, compared the immunogenicity of VLA15 after administration of two or three primary series doses. In the sub-analysis of adult participants (18-65 years old), VLA15 was immunogenic with both vaccination schedules tested. These data are consistent with the strong immunogenicity profile observed for this age group in previous Phase 2 s

Yahoo | February 4, 2022

Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate

Dose selection complete for planned Phase 3 trial, expected to be initiated in 3Q2022Sub-analysis compared the immunogenicity of VLA15 in adults 18-65 years of age after administration of two or three primary series dosesStronger immune response observed in adult participants who received three priming doses vs. two priming doses; pediatric study ongoing with initial data expected in 1H2022Three-dose priming schedule selected for use in adults moving forward Saint-Herblain (France) and New York,

Yahoo | February 4, 2022

Read More 'VALN' Stories Here

VALN Price Returns

1-mo -2.52%
3-mo -26.94%
6-mo -63.72%
1-year -6.04%
3-year N/A
5-year N/A
YTD -56.03%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4154 seconds.